TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19638647

Group type: EXPERIMENTAL
Intervention: Immediate large loop excision
Number of subjects: 1983

Group type: COMPARATOR
Intervention: Biopsy and selective recall
Number of subjects: 1983
Study: 17505703

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Chymopapain
Number of subjects: 22

Group type: COMPARATOR
Intervention: Chemonucleolysis with chymopapain
Number of subjects: 22
Study: 15342160

Group type: EXPERIMENTAL
Intervention: Isokinetic test for inversion at 120 degrees/s
Number of subjects: 11

Group type: COMPARATOR
Intervention: Isokinetic test for eversion at 120 degrees/s
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isokinetic test for inversion and eversion at 30 degrees/s
Number of subjects: 11
Study: 12377958

Group type: COMPARATOR
Intervention: EPI alone (60 mg/m(2) on days 1 and 2 every 21 days)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: EPI and CDDP (30 mg/m(2) on days 1 and 2 every 21 days)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: EPI and LND (450 mg orally daily, given continuously)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: EPI, CDDP, and LND
Number of subjects: 371
Study: 9846090

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: TCu‐380A and Nova T (R.)
Number of subjects: 55
Study: 7863045

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) 50-100 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 54
Study: 2768611

Group type: EXPERIMENTAL
Intervention: Behavioral skills training program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Feelings-based program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control presentation
Number of subjects: 100
Study: 821075

Group type: EXPERIMENTAL
Intervention: Orally administered thyrotropin-releasing hormone (TRH) at a dosage of 200 to 300 mg daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31610635

Group type: EXPERIMENTAL
Intervention: Female infants at 7 months of age for tetanus and filamentous haemagglutinin
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Female infants at 13 months of age for polio type 3, pneumococcal serotype 6A and measles
Number of subjects: 398

Group type: COMPARATOR
Intervention: Sex influence on seroprotection rates
Number of subjects: 398

Group type: COMPARATOR
Intervention: Delivery mode, feeding method and antibiotic exposure
Number of subjects: 398
Study: 31284771

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg once daily
Number of subjects: 3864

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg twice daily
Number of subjects: 3864

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 3864

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3864
Study: 28599630

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1.8 g daily, containing 1.08 g of EPA and 0.72 g of DHA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study: 26093656

Group type: EXPERIMENTAL
Intervention: Memantine with reactivation of associative cue‐smoking memories
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Memantine without reactivation of associative cue‐smoking memories
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo with reactivation of associative cue‐smoking memories
Number of subjects: 59
Study: 22697811

Group type: EXPERIMENTAL
Intervention: Home-based progressive resistance exercise programme
Number of subjects: 13

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 13
Study: 21709652

Group type: EXPERIMENTAL
Intervention: i.v. diazepam
Number of subjects: 36

Group type: COMPARATOR
Intervention: i.v. midazolam 1 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: i.v. midazolam 3 mg
Number of subjects: 36
Study: 18339606

Group type: EXPERIMENTAL
Intervention: myeloperoxidase (MPO)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: soluble CD40 ligand (sCD40L)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: MPO, BNP, and cTnI stratification
Number of subjects: 1524
Study: 16895771

Group type: EXPERIMENTAL
Intervention: VT cycle length < 350 ms
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (EF) < 25%
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: First VT cycle length
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: QRS duration
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Underlying heart disease
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Indication of ICD implantation
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 158
Study: 14711553

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, p.o. b.i.d.)
Number of subjects: 20
Study: 11355560

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg single dose)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Iron‐folate supplements (36 mg iron and 5 mg folate daily)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (neither albendazole nor iron‐folate supplements)
Number of subjects: 125
Study: 9146577

Group type: EXPERIMENTAL
Intervention: Vaginal mucosal immunization (vaccine treated)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 91
Study: 8174435

Group type: EXPERIMENTAL
Intervention: Strenuous exercise (10 min pedaling at 85% predicted maximum heart rate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 6
Study: 3354431

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31865505

Group type: EXPERIMENTAL
Intervention: Periodized circuit training (CT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Conventional strength training (ST)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Educational protocol (EP)
Number of subjects: 61
Study: 29342272

Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding decision-making about food and drink, dietary supplements, medications, alcohol, and recreational drugs.
Number of subjects: 20
Study: 28126600

Group type: EXPERIMENTAL
Intervention: Romifidine 60 μg/kg IV (R60)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Romifidine 80 μg/kg IV (R80)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Romifidine 100 μg/kg IV (R100)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Romifidine 40 μg/kg IV (R40)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acepromazine 0.1 mg/kg IV (ACE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (0.9%, 5 mL IV)
Number of subjects: 0
Study: 26150231

Group type: EXPERIMENTAL
Intervention: Rollator
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Draisine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unaided walking
Number of subjects: 15
Study: 23176568

Group type: EXPERIMENTAL
Intervention: Nanoparticle paclitaxel 300 mg/m² (NP300)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Nanoparticle paclitaxel 220 mg/m² (NP220)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Cremophor paclitaxel 175 mg/m² (CP175)
Number of subjects: 194
Study: 22000624

Group type: EXPERIMENTAL
Intervention: Assessment of oxygenation, blood cultures, rapid initiation of antibiotic therapy <4 hours, appropriate selection of antibiotic therapy
Number of subjects: 2076

Group type: COMPARATOR
Intervention: 0 to 2 processes of care performed
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: 3 processes of care performed
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: All 4 processes of care performed
Number of subjects: 2076
Study: 18434883

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 12/1.5 g/day after a loading dose of 4/0.5 g
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 16/2 g/day after a loading dose of 4/0.5 g
Number of subjects: 40
Study: 16256232

Group type: EXPERIMENTAL
Intervention: CHART treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 12634635

Group type: EXPERIMENTAL
Intervention: Sacrospinous cervicocolpopexy with uterine conservation (Group A)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with sacrospinous colpopexy (Group B)
Number of subjects: 109
Study: 11186163

Group type: EXPERIMENTAL
Intervention: Alzheimer disease patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Older adult controls
Number of subjects: 32
Study: 8618367

Group type: EXPERIMENTAL
Intervention: Active Compression-Decompression (ACD) CPR
Number of subjects: 1784

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 1784
Study: 1318678

Group type: EXPERIMENTAL
Intervention: Daptomycin 2.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin 3.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin 4.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin 6.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin 1.0 mg/kg (14C-labeled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin 0.5 to 6.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin (predicted effective doses)
Number of subjects: 0
Study: 3871754

Group type: EXPERIMENTAL
Intervention: TENS just above the patient's ability to perceive the stimuli
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (electrodes applied without electrical stimulation)
Number of subjects: 62
Study: 30741801

Group type: EXPERIMENTAL
Intervention: Oxytocin (30 units in 500 mL of intravenous fluid)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (500 mL of intravenous fluid alone)
Number of subjects: 160
Study: 29457516

Group type: EXPERIMENTAL
Intervention: Chocolate-based products
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tested biscuit
Number of subjects: 20
Study: 27724859

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.15 μg·kg−1·min−1) followed by immobility
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standardized movement intervention (head-trunk movement)
Number of subjects: 16
Study: 24689056

Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NHA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 38
Study: 22157743

Group type: EXPERIMENTAL
Intervention: ASRA Checklist
Number of subjects: 25

Group type: COMPARATOR
Intervention: No Checklist
Number of subjects: 25
Study: 20499248

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 33
Study: 17294149

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs combined with psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polypharmacy
Number of subjects: 0
Study: 16118079

Group type: EXPERIMENTAL
Intervention: 6 courses of anthracycline-based chemotherapy (CT group)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 1146
Study: 12270028

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg taken 4 hours before expected time of sex for 6 months
Number of subjects: 87
Study: 10052020

Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C capsule daily during weeks 4-5
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo capsule daily during weeks 1-3
Number of subjects: 9
Study: 7577894

Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) in preloads
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Water in preloads
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fat in preloads
Number of subjects: 74

Group type: COMPARATOR
Intervention: Rice and macaroni preloads
Number of subjects: 74
Study: 2174464

Group type: EXPERIMENTAL
Intervention: Bolus regimen of etoposide (VP‐16) and cisplatin (CDDP)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Infusion regimen of etoposide (VP‐16) and cisplatin (CDDP)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Bolus regimen
Number of subjects: 113

Group type: COMPARATOR
Intervention: Infusion regimen
Number of subjects: 113
Study: 6999637

Group type: EXPERIMENTAL
Intervention: Danazol treatment for 6 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Danazol combined with conservative surgery
Number of subjects: 36
Study: 31014270

Group type: EXPERIMENTAL
Intervention: Tolvaptan therapy
Number of subjects: 0
Study: 29522648

Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide 0.6 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Darifenacin 10 mg or 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27784322

Group type: EXPERIMENTAL
Intervention: T piece
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0 cmH2O
Number of subjects: 17

Group type: COMPARATOR
Intervention: PSV 7 and PEEP 7 cmH2O
Number of subjects: 17

Group type: COMPARATOR
Intervention: PSV 0 and PEEP 7 cmH2O
Number of subjects: 17

Group type: COMPARATOR
Intervention: PSV 7 and PEEP 0 cmH2O
Number of subjects: 17
Study: 24222312

Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy and hypofractionated external beam radiotherapy (EBRT) with long-term androgen deprivation therapy (ADT)
Number of subjects: 178
Study: 22080619

Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nebulized epinephrine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study: 19329101

Group type: EXPERIMENTAL
Intervention: Barriers to Care Questionnaire (BCQ)
Number of subjects: 252
Study: 17484092

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg per day
Number of subjects: 844

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg per day
Number of subjects: 844
Study: 15139565

Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 60
Study: 12270235

Group type: EXPERIMENTAL
Intervention: 3D Augmented Reality guidance system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard ultrasound-guided needle biopsy
Number of subjects: 50
Study: 10049989

Group type: EXPERIMENTAL
Intervention: Pacifier introduction by 6 weeks
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Pacifier introduction before 2 weeks or before 6 weeks
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Pacifier introduction
Number of subjects: 265
Study: 7572902

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg daily)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 2178566

Group type: EXPERIMENTAL
Intervention: Acetyl-salicylic acid (ASA) 1000 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Acetyl-salicylic acid (ASA)
Number of subjects: 66
Study: 89499

Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIg) 0.5 ml/kg within 48 hours after birth and 0.16 ml/kg every month for 6 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIg)
Number of subjects: 41
Study: 31871245

Group type: EXPERIMENTAL
Intervention: Nudge + STOMP
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Nudge alone
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: STOMP alone
Number of subjects: 517

Group type: COMPARATOR
Intervention: Control
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: STOMP
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Higher risk perception
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Parental past opioid misuse
Number of subjects: 517
Study: 30079635

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion (1 mg bolus over 30 minutes followed by 2 μg/kg/h continuous infusion)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (0.9% saline at the same volume and rate)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 27659394

Group type: EXPERIMENTAL
Intervention: Canady Hybrid Plasma Scalpel (CHPS)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Aquamantys Bipolar Sealer (BS)
Number of subjects: 244
Study: 26323293

Group type: EXPERIMENTAL
Intervention: Chewing gum for five days postoperatively
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 106
Study: 23507223

Group type: EXPERIMENTAL
Intervention: Green tea (4 cups per day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Green tea extract (2 capsules and 4 cups water per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (4 cups water per day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Green tea extract
Number of subjects: 35
Study: 22166241

Group type: EXPERIMENTAL
Intervention: Endostatin in patients with gastric cancer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EGF in patients with gastric cancer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endostatin before surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endostatin after surgery
Number of subjects: 20
Study: 19470058

Group type: EXPERIMENTAL
Intervention: Strip patch test (SPT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional patch test (PT)
Number of subjects: 30
Study: 17052563

Group type: COMPARATOR
Intervention: i.v. ketamine 1 mg/kg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: i.m. ketamine 4 mg/kg
Number of subjects: 225
Study: 10370910

Group type: EXPERIMENTAL
Intervention: Budipine (n = 7)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Budipine (open-label study, n = 9)
Number of subjects: 25
Study: 8522684

Group type: EXPERIMENTAL
Intervention: Intracoronary isosorbide dinitrate (2 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 36

Group type: COMPARATOR
Intervention: Post-isosorbide dinitrate measurements
Number of subjects: 36
Study: 1862731

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123
Study: 6303624

Group type: EXPERIMENTAL
Intervention: Thallium-201 scintigraphy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gated blood pool imaging
Number of subjects: 91

Group type: COMPARATOR
Intervention: Thallium score less than 7
Number of subjects: 91

Group type: COMPARATOR
Intervention: Ejection fraction greater than 35%
Number of subjects: 91

Group type: COMPARATOR
Intervention: Concordant high-risk scintigrams
Number of subjects: 91

Group type: COMPARATOR
Intervention: Concordant low-risk studies
Number of subjects: 91

Group type: COMPARATOR
Intervention: Discordant results
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-risk thallium or blood pool scintigraphic results
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Thallium score of 7 or greater
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combination of thallium score, appearance of Q waves, and ejection fraction
Number of subjects: 91

Group type: COMPARATOR
Intervention: Calculated chance of death less than 50%
Number of subjects: 91
Study: 30215545

Group type: EXPERIMENTAL
Intervention: Leniolisib (CDZ173), single oral dose of 400 mg
Number of subjects: 0
Study: 29127604

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 4190

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (ACRT)
Number of subjects: 4190

Group type: COMPARATOR
Intervention: Postoperative observation (Control)
Number of subjects: 4190
Study: 26823180

Group type: EXPERIMENTAL
Intervention: Intensive journal club treatment arm
Number of subjects: 52

Group type: COMPARATOR
Intervention: Self-study group
Number of subjects: 52
Study: 25027335

Group type: COMPARATOR
Intervention: 3D‐CPA in high-grade CIN group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3D‐CPA in early cervical cancer group
Number of subjects: 90

Group type: COMPARATOR
Intervention: MVD in high-grade CIN group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Correlation of MVD with ultrasound parameters
Number of subjects: 90

Group type: COMPARATOR
Intervention: Postoperative CIN group
Number of subjects: 90
Study: 22166903

Group type: EXPERIMENTAL
Intervention: Salbutamol (15 μg/kg ideal bodyweight per h) for up to 7 days
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo for up to 7 days
Number of subjects: 326
Study: 20702657

Group type: EXPERIMENTAL
Intervention: Recombinant EBA‐175 vaccine with aluminum phosphate adjuvant (5, 20, 80, or 160 μg) administered at 0, 1, and 6 months
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Recombinant EBA‐175 vaccine with aluminum phosphate adjuvant (3 doses at any concentration)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17717960

Group type: EXPERIMENTAL
Intervention: Ketamine (0, 1, or 10 mmol/L)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Glutamate (0.2 mL, 1 mol/L)
Number of subjects: 47
Study: 15834239

Group type: EXPERIMENTAL
Intervention: Computer Group (interactive computer program before counseling)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Counselor Group (standard genetic counseling)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Computer Group
Number of subjects: 211

Group type: COMPARATOR
Intervention: Counselor Group
Number of subjects: 211